NBTXR3 First in Class Radioenhancer
Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.
Only one administration
Fits into existing standard of care:
One product addressing areas of high unmet medical needs.
See moreRecent Press Releases
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
Voting Rights and Shares Capital of the Company
ALL NANOBIOTIX PRESS RELEASES
Events
Meet Nanobiotix International events and conferences
JOIN US
“Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”
Anne-Juliette Hermant
Chief People Officer